Skip to main content
JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD. logo

JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD. — Investor Relations & Filings

Ticker · 688488 ISIN · CNE1000041S6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 930 across all filing types
Latest filing 2026-05-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688488

About JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD.

http://en.aidea.com.cn/

Jiangsu Aidea Pharmaceutical Group Co., Ltd. is a biopharmaceutical enterprise focused on the research, development, manufacturing, and commercialization of innovative drugs. The company specializes in therapeutic areas with significant unmet medical needs, particularly anti-HIV treatments and anti-inflammatory medications. Its core product portfolio includes Ainuovirine (ACC007), a third-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV-1 infection, and Ainuomiti (ACC008), a single-tablet triple-combination regimen. Aidea Pharmaceutical maintains an integrated R&D platform and advanced manufacturing facilities to support its pipeline of small molecule drugs and biological products. The company aims to provide accessible and effective treatment solutions through continuous innovation in drug discovery and clinical development.

Recent filings

Filing Released Lang Actions
艾迪药业关于达芦那韦原料药获得上市申请批准通知书的自愿性披露公告
Regulatory Filings Classification · 89% confidence The document is a voluntary regulatory announcement by Jiangsu Aidis Pharmaceutical Group disclosing that its subsidiary received approval from China’s National Medical Products Administration for the marketing application of an active pharmaceutical ingredient (Darunavir). It is not an annual or interim financial report, not a dividend or share transaction notice, not management or proxy materials. It is a general regulatory filing to inform investors of a material company development. Therefore, it fits the fallback category Regulatory Filings (RNS).
2026-05-24 Chinese
艾迪药业关于变更保荐机构后重新签订募集资金专户存储三方监管协议的公告
Regulatory Filings Classification · 85% confidence The document is a corporate compliance announcement filed on the Shanghai Stock Exchange regarding the re-signing of the three-party supervision agreement for the storage and use of previously raised IPO/private placement funds. It details the agreement terms, bank accounts, and regulatory references, but does not itself present financial statements or constitute a standalone financial report. It is neither an earnings release nor a capital raise disclosure per se but a routine regulatory filing to comply with listing rules. This fits the fallback category “Regulatory Filings.”
2026-05-21 Chinese
艾迪药业2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2025年年度股东会决议公告" which translates to "2025 Annual General Meeting (AGM) Resolution Announcement." It details the date and location of the AGM, attendance, voting results on various proposals including the 2025 annual report, financial statements, profit distribution, director remuneration, and a specific share issuance plan. The document also includes legal opinions confirming the legality and validity of the meeting and resolutions. The content is focused on the announcement of the AGM resolutions and voting results rather than the full annual report or financial statements themselves. The document length is about 10,787 characters, which is consistent with a detailed announcement but not a full report. Therefore, this document fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-20 Chinese
艾迪药业关于重大资产重组事项的进展公告
M&A Activity Classification · 90% confidence The document is a detailed progress announcement (“进展公告”) regarding a major asset reorganization transaction (acquisition of a 31.161% equity stake in Nanjing Nanda Pharmaceutical). It outlines the signing of equity purchase agreements, regulatory disclosures on the Shanghai Stock Exchange, installment payments, audit and legal opinions, and subsequent performance‐linked payments. This is clearly an ongoing M&A transaction update rather than an annual or interim report, earnings release, board change, or financing notice. Therefore, it fits the M&A Activity category.
2026-04-14 Chinese
国联民生证券承销保荐有限公司关于江苏艾迪药业集团股份有限公司重大资产购买之2025年度持续督导核查意见暨持续督导总结报告
M&A Activity Classification · 90% confidence The document is an independent financial advisor’s continuous supervision and summary report on a major asset purchase (重大资产购买) by Jiangsu Addi Pharmaceutical Group in 2025, including transaction structure, due diligence opinions, implementation status, and party commitments. It is not a regular annual or audit report but rather a disclosure relating to a major asset reorganization and purchase transaction, fitting the definition of M&A Activity (Code: TAR).
2026-04-14 Chinese
艾迪药业2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is titled as "2025 年年度股东会会议资料" which translates to "2025 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items for the 2025 annual shareholders meeting, including reports such as the Board of Directors' work report, independent directors' reports, annual report and its summary, financial statements, profit distribution plans, and proposals related to share issuance and remuneration. The document also includes meeting procedures, voting instructions, and legal compliance notes. The content is clearly materials prepared for and to be presented at the Annual General Meeting, rather than the annual report itself or an announcement of the report. The length is substantial (15,000 characters), indicating it is the full meeting materials, not just a brief announcement. Therefore, the document fits the category of AGM Information (AGM-R).
2026-04-10 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.